February 11, 2020 / 10:34 PM / 14 days ago

BRIEF-CSL's Privigen Granted Orphan-Drug Designation For The Investigational Treatment Of Systemic Sclerosis (Ssc)

Feb 11 (Reuters) - CSL Ltd:

* PRIVIGEN® (IMMUNE GLOBULIN INTRAVENOUS (HUMAN), 10% LIQUID) GRANTED ORPHAN-DRUG DESIGNATION FOR THE INVESTIGATIONAL TREATMENT OF SYSTEMIC SCLEROSIS (SSC) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below